TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
RS Herbst, D Prager, R Hermann, V Miller… - Journal of Clinical …, 2004 - ascopubs.org
7011 Background: Tarceva™(erlotinib) is a potent reversible HER1/EGFR tyrosine kinase
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …
Randomized phase II trial of erlotinib beyond progression in advanced erlotinib-responsive non-small cell lung cancer
Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2004 - ascopubs.org
7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …
inhibitor with single-agent antitumor activity and has shown additive effects when added to …
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non–small-cell lung cancer: the TORCH randomized trial
C Gridelli, F Ciardiello, C Gallo, R Feld… - Journal of Clinical …, 2012 - ascopubs.org
Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy …
FA Shepherd, J Pereira, TE Ciuleanu… - Journal of Clinical …, 2004 - ascopubs.org
7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
[HTML][HTML] Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line …
Background In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …
Phase II study of erlotinib for chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets
DH Lee, SW Kim, C Suh, YH Han, JS Lee - Cancer chemotherapy and …, 2011 - Springer
Purpose This phase II study evaluated efficacy of single-agent erlotinib for chemotherapy-
naïve patients with advanced/metastatic NSCLC who were ineligible for platinum doublets …
naïve patients with advanced/metastatic NSCLC who were ineligible for platinum doublets …
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)
MH Cohen, JR Johnson, S Chattopadhyay… - The …, 2010 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non–small-cell lung …
FR Hirsch, F Kabbinavar, T Eisen, R Martins… - Journal of clinical …, 2011 - ascopubs.org
Purpose Erlotinib prolongs survival in patients with advanced non–small-cell lung cancer
(NSCLC). We report the results of a randomized, phase II study of erlotinib alone or …
(NSCLC). We report the results of a randomized, phase II study of erlotinib alone or …
[HTML][HTML] Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
M Ranson, M Reck, A Anthoney, AR Hanauske… - Annals of oncology, 2010 - Elsevier
Background Erlotinib and pemetrexed are approved single agents for second-line treatment
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …